Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company...
Pharmaceutical
GE HealthCare Management to Present at Upcoming Investor Conferences
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), is announcing today that its Vice President and Chief Financial Officer, Jay Saccaro, will be...
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
Conference Call Scheduled for Thursday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite...
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024...
Skinvisible Announces Significant Progress in Licensee’s Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising...
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
KNOXVILLE, TN, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that...
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
BOSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer CenterTrial is Supported by...
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
Up to 16 million adults in the US are living with a neurological disease, the leading cause of physical and...
Evoke Pharma Announces Closing of $7.5 Million Public Offering
Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in FullSOLANA BEACH, Calif., Feb. 14, 2024...
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose...
Healthcare Triangle Unveils New SaaS Solutions to Drive Digital Transformation and AI Integration in Healthcare
Company positioned at forefront of $208 billion global AI in healthcare market by 2030 PLEASANTON, Calif., Feb. 14, 2024 (GLOBE...
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical...
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA® (aflibercept) over EYLEA alone in wet AMD Enrollment of...
Hemogenyx Pharmaceuticals PLC Announces CBR Intranasal Delivery
Chimeric Bait Receptors for Combatting Airborne Viral Infections Can Be Delivered IntranasallyLONDON, UK / ACCESSWIRE / February 14, 2024 /...
Health Advance Partners Closes SingleTimeMicroneedles’ Pre-Seed Funding Round
Health Advance Partners Agree to Equity Stake in SingleTimeMicroneedles at a $3.5 Million ValuationSTORRS, CT / ACCESSWIRE / February 13,...
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering...
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole...
Akanda Corp. Discusses Positive Trends in UK Cannabis Market
London, United Kingdom--(Newsfile Corp. - February 13, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), provides an overview...